Key takeaways
- RUO is a statement of intended use, not a quality grade; it does not imply GMP manufacture, so lot-specific documentation still matters.
- Therapeutic goods generally must be entered on the ARTG before lawful supply, and the TGA states that a research use only disclaimer does not make supply of peptide products lawful.
- The Poisons Standard (SUSMP) takes legal effect through state and territory legislation, so controls on a substance depend on its scheduling and your jurisdiction.
- Laboratories carry responsibilities for approvals, records, secure storage, safety and disposal, while responsible suppliers label clearly, make no health claims and refuse orders indicating human use.
“Research Use Only” is printed on antibody datasheets, assay kits, analytical standards, instrument manuals and peptide vials. It is widely used and widely misread: some treat it as a quality grade, others as a legal shield, and it is neither. This guide sets out what the label actually communicates, how it sits against Australia’s therapeutic goods framework, and what laboratories and suppliers each need to do.
Where the RUO label comes from
The designation grew up around reagents, instruments and diagnostics. Manufacturers needed a way to supply products for research without implying they were fit for clinical decisions. In the United States, for instance, the FDA issued guidance in 2013 on in vitro diagnostic products labelled for research use only or investigational use only, which distinguishes those products from diagnostics that have been through the premarket review needed for clinical use.
RUO is a statement of intended use. It tells the recipient that the manufacturer has not validated the product for diagnosis, treatment or any application in people, and that no regulator has assessed it for those purposes. It sits well apart from two other categories: diagnostic devices assessed for clinical performance, and medicines manufactured under good manufacturing practice (GMP) for therapeutic supply.
In Australia, the relevant boundary is the definition of therapeutic goods in section 3 of the Therapeutic Goods Act 1989. The TGA summarises that definition as products for use in humans in connection with things such as preventing, diagnosing, curing or alleviating a disease, or influencing, inhibiting or modifying a physiological process. For background on the materials themselves, see What Are Research Peptides?
What RUO tells you about quality, and what it does not
RUO is not a purity specification. Two vials carrying identical RUO statements can differ widely in identity confirmation, purity, counter-ion and water content, and endotoxin levels. The label says nothing about any of these.
It also does not imply GMP. The TGA describes GMP as a set of principles and procedures that help ensure therapeutic goods are of high quality, built on the idea that quality has to be built into each batch rather than tested in at the end. Research reagents are generally not made under that system. Some reagent makers run certified quality management systems; confirm this rather than assume it, and remember it is not a therapeutic manufacturing licence.
For research purposes, documentation does the real work. A lot-specific certificate of analysis should state the analytical methods used, the results against specification, the test date and who performed the testing. If a result cannot be traced back to a characterised lot, it is hard to defend in a manuscript or an audit. Our guide on how to interpret a peptide certificate of analysis covers what to look for.
RUO reagents compared with therapeutic goods on the ARTG
According to the TGA, therapeutic goods must be entered in the Australian Register of Therapeutic Goods (ARTG) before they can be lawfully supplied in, imported into or exported from Australia, unless they are exempt or otherwise authorised. Goods are entered after the TGA has assessed higher-risk products for quality, safety and, where appropriate, efficacy, or has validated applications for lower-risk products.
| Aspect | RUO reagent | Therapeutic good on the ARTG |
|---|---|---|
| What the label means | A supplier’s statement that the product is intended for laboratory research only | An entry on a national register held by a sponsor who is responsible for meeting regulatory requirements |
| Quality system | Set by the manufacturer; not GMP by default, so lot documentation must be checked | Manufacturing subject to GMP licensing or clearance requirements appropriate to the product type |
| Regulatory assessment | None arises from the label itself | TGA assessment or validation, scaled to risk |
| Permitted use | In-vitro and laboratory research under institutional controls; not for human or animal use | Supply and use in line with its ARTG entry, scheduling and any prescription requirements |
| Oversight | Institutional safety committees, work health and safety law, and poisons or therapeutic goods law wherever they apply to the substance | TGA post-market monitoring and advertising controls, plus state and territory poisons legislation |
What an RUO label cannot do
An RUO statement does not make a substance lawful to administer to people or animals, and it does not change how the substance is regulated.
The TGA has addressed peptides specifically. Its safety advisory of 13 April 2026 on unapproved peptide products states that peptide products are regulated as therapeutic goods under the Act, and that a “research use only” disclaimer does not make supply lawful. On its own, the advisory says, such a disclaimer does not change a product’s regulatory status, does not permit importation, and does not remove advertising or supply obligations. It adds that state and territory laws may impose further controls on sale, supply and possession.
Scheduling also operates independently of any label. The Poisons Standard, also known as the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP), classifies substances into Schedules, and the TGA explains that those Schedules are given legal effect through state and territory legislation. The current edition is the Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. Whether a given substance can be purchased, held or stored by your organisation, and under what permits or storage conditions, depends on its scheduling and on the law in your jurisdiction. Those rules are not identical across Australia, so check the current instrument and confirm with your state or territory medicines and poisons regulation unit. The TGA publishes contact details for each unit.
The practical rule: an RUO label describes intended use. It does not grant any authority to supply, import, possess or use a substance.
Responsibilities that sit with the purchasing laboratory
Once a reagent arrives, the institution and the people using it carry most of the day-to-day obligations. Detail varies by substance, jurisdiction and institution, but the themes are consistent.
Approvals
Work should sit within an approved project, with sign-off from the relevant biosafety or chemical safety committee where your institution requires it. Reagents sold for in-vitro use are not a substitute for the separate approvals any animal work needs, and they should not be assumed suitable for it.
Records
Keep receipt records, lot numbers, certificates of analysis, storage location, usage logs and disposal records. For scheduled substances, your jurisdiction may prescribe specific record-keeping, so check before the first order.
Storage, safety and disposal
Store materials securely with access limited to trained staff, keep safety data sheets on hand, complete a risk assessment, and dispose of waste through your institution’s chemical or biological waste procedures. Our article on laboratory handling best practices for peptides covers storage and reconstitution in the lab.
What a responsible supplier should be doing
Suppliers cannot control what happens after delivery, but reasonable practice includes:
- Clear labelling: product name, lot number, quantity, storage conditions and an explicit statement that the product is not for human or veterinary use.
- No health claims: no therapeutic, performance or cosmetic claims in listings, social media or customer correspondence. The TGA has flagged that promoting unapproved peptide products is likely to breach advertising laws.
- Eligibility checks: confirming buyers are adults and collecting organisation details where appropriate.
- Documentation: lot-specific certificates of analysis and safety data sheets available before purchase.
- Refusing risky orders: declining or cancelling orders that suggest personal or human use, such as questions about dosing or personal use.
- Honest labels: never obscuring ingredients or relabelling to avoid scrutiny, a practice the TGA specifically calls out.
None of these practices changes a product’s regulatory status. They are the baseline for acting in good faith, not a substitute for compliance. Our terms of sale and legal information set out the conditions that apply to our own orders.
A practical compliance checklist for Australian laboratories
- Confirm the work is in-vitro or otherwise within an approved project scope.
- Check the substance against the current Poisons Standard and your state or territory poisons legislation.
- Contact your medicines and poisons regulation unit if any permit or licence may be required.
- Obtain any biosafety or chemical safety approvals your institution requires before ordering.
- Request the lot-specific certificate of analysis and safety data sheet, and review both on receipt.
- Record receipt, lot number, storage location and custodian.
- Store securely, with access limited to trained staff and conditions matched to the product.
- Maintain a usage log that reconciles quantities received, used and remaining.
- Dispose of waste through approved institutional channels and record it.
- Review supplier documentation and your own procedures at least annually, and whenever regulator guidance changes.
Aussie Peptide Co supplies peptides strictly for in-vitro laboratory research and will decline orders that indicate any other purpose. If you have a documentation question or need a certificate for a specific lot, please get in touch.
This article is general information only and is not legal advice. Regulatory requirements vary by substance and by state or territory, and they change over time. Confirm your obligations with the TGA, your state or territory regulator, or a qualified adviser.
References & further reading
- Understanding your responsibilities when importing, compounding and supplying unapproved peptide products Therapeutic Goods Administration (TGA)
- What are 'therapeutic goods'? Therapeutic Goods Administration (TGA)
- The Poisons Standard and scheduling of medicines and chemicals Therapeutic Goods Administration (TGA)
- Therapeutic Goods Act 1989 Federal Register of Legislation
- Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 Federal Register of Legislation
Frequently asked questions
No. Research use only describes intended use, not quality. Two products with the same RUO statement can differ widely in identity confirmation, purity and contaminants, and the label does not imply manufacture under good manufacturing practice. For research work, the lot-specific certificate of analysis matters more than the label. Check the analytical methods, results against specification, test date and who did the testing.
The label alone does not make supply lawful. In a safety advisory published on 13 April 2026, the TGA stated that peptide products are regulated as therapeutic goods and that a research use only disclaimer does not change a product's regulatory status, permit importation, or remove advertising or supply obligations. State and territory laws may add further controls. This is general information, so seek advice on your specific situation.
Look the substance up in the current Poisons Standard, published on the Federal Register of Legislation. The Schedules take legal effect through state and territory legislation, so permits, storage and record-keeping rules can differ between jurisdictions. If a substance appears in a Schedule, or you are unsure, contact your state or territory medicines and poisons regulation unit. The TGA website lists contact details for each.
At a minimum, record the date received, supplier, lot number, quantity, storage location and responsible custodian. Keep the certificate of analysis and safety data sheet for each lot. A usage log should reconcile amounts received, used and remaining, and disposal should be recorded too. Scheduled substances may carry extra record-keeping requirements in your state or territory, so confirm those before you place the first order.
Our in-house team writes laboratory-focused guides on peptide documentation, testing, storage and handling. Content is reviewed against published analytical practice and is provided strictly for research use.
